Memory Support System for Older Chinese Americans With Mild Cognitive Impairment

Not Applicable

Recruiting

• Conditions: Mild Cognitive Impairment (MCI)

• Registration Number: NCT07142499
• Lead Sponsor: Icahn School of Medicine at Mount Sinai

Brief Summary

The Memory Support System (MSS) from the Healthy Action to Benefit Independence \& Thinking® (HABIT) Program is an evidence-based, non-pharmacological intervention for mild cognitive impairment (MCI). Despite the clinical benefits and feasibility, the MSS was primarily developed and used with non-Hispanic White, English-speaking adults. Racial/ethnic minority groups are chronically under-enrolled in clinical trials for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) due to lack of linguistically and culturally appropriate adaptation of assessment measures and intervention protocols. The purpose of this research study is to examine whether the MSS from HABIT can help Chinese American older adults with mild thinking and memory problems. Target recruitment is 60 Chinese American adults who are primarily Mandarin- (n=30) and Cantonese-speaking (n=30). Forty participants will participate in the trainer-led day planner training and 20 will participate in self-study of the day planner and receive brain health education. Each participant will also be asked to identify a study partner to participate with them.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-07-29
• Status Verified: 2025-08
• Study First Submitted: 2025-08-19
• Study First Submitted QC: 2025-08-19
• Last Update Submitted: 2025-08-19
• Study First Posted: 2025-08-26
• Last Update Posted: 2025-08-26
• Primary Completion: 2025-10
• Study Completion: 2026-05-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Recruitment rate	baseline, week 1 of intervention session	Recruitment rate will be measured by dividing the number of enrollees over the number of total potential participants approached.
Retention rate	baseline, treatment end (4-9 weeks)	Retention rate will be measured by dividing the number of enrollees who remain in the study over the total number of enrollees.
Completion rate	baseline, treatment end (4-9 weeks)	Completion rate will be measured by dividing the number of enrollees who complete all study procedures over the number of total enrollees.

Secondary Outcome Measures

Name	Time	Method
The Pillbox Test	at baseline, treatment end (4-9 weeks), and 8-week follow-up	The pillbox Test will also be used to assess performance based IADLs, min score is 0 and max score is 5. A higher score on the pillbox test typically indicates better cognitive function and medication management skills.
Dementia Rating Scale-2 (DRS-2)	at baseline, treatment end (4-9 weeks), and 8-week follow-up	Cognition will be measured using the Dementia Rating Scale-2 (DRS-2). The assessment provides quantitative assessment on attention, initiation/perseveration, construction, conceptualization, and memory. Full score range from 0-144, with higher score indicating better health outcome. It will be used to assess whether treatment group participants demonstrate improved cognitive performance beyond expected practice effect in comparison to their control group counterparts.
Chronic Disease Self-Efficacy Scales	at baseline, treatment end (4-9 weeks), and 8-week follow-up	Self-efficacy for memory will be assessed using modified, selected items from the Chronic Disease Self-Efficacy Scales. Total scores range from 9 to 90, with higher scores indicating greater memory self-efficacy.
Everyday Cognition questionnaire	at baseline, treatment end (4-9 weeks), and 8-week follow-up	Functional status will be assessed using selected items from the informant-rated version of the Everyday Cognition (ECog) questionnaire to evaluate a participant's ability to perform everyday tasks in areas of memory and executive functioning.; Full ECog is comprised of 39 items, each item score 1-4. Total score range from 39-156, with higher score indicating poorer health outcome.
Functional Activities Questionnaire (FAQ)	at baseline, treatment end (4-9 weeks), and 8-week follow-up	The FAQ, consisting of 10 items assessing instrumental activities of daily living (IADLs), is an informant-based questionnaire, to evaluate functional abilities. The min score is 0 and max score is 30. A higher score generally indicates poorer functioning and ability to perform daily activities.
Quality of Life in Alzheimer Disease	at baseline, treatment end (4-9 weeks), and 8-week follow-up	Quality of life will be measured using the Quality of Life in Alzheimer Disease instrument, a 13-item measure that has been utilized in MCI and with study partners to assess health-related quality of life. Quality of life of both participant and study partner will be assessed. Total score range 13-52, with higher scores indicating greater quality of health.
Neuropsychiatric Inventory Questionnaire (NPI-Q) - Severity	at baseline, treatment end (4-9 weeks), and 8-week follow-up	Neuropsychiatric symptoms will be assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). The instrument is completed by a study partner in which a series of questions are described to assess 12 neuropsychiatric symptoms. If the symptom is present within the last month, the study partner will then rate the severity levels using a 3-point Likert scale (1=mild; 2=moderate; 3= severe).; Total score range from 12-36, with higher score indicating greater severity.
Center for Epidemiologic Studies Depression Scale	at baseline, treatment end (4-9 weeks), and 8-week follow-up	Depression will be measured using the Center for Epidemiologic Studies Depression Scale, a 20-item self-report scale with 3-point Likert-type response options ranging from 1 (rarely or none of the time or \< 1 day) to 3 (most or all of the time or 5-7 days). Total scores range from 0 to 60, with higher scores suggesting greater symptoms of depression. Depression symptomology of both participant and study partner will be assessed.
Anxiety Inventory Form	at baseline, treatment end (4-9 weeks), and 8-week follow-up	Anxiety will be measured using the Anxiety Inventory Form, a 10-item rating scale modified from the State- Trait Anxiety Inventory by the Resources for Enhancing Alzheimer's Caregiver Health project. Total scores range from 10 to 40, with higher scores indicating higher levels of anxiety. Anxiety symptomology of both participant and study partner will be assessed.
Pittsburgh Sleep Quality Index	at baseline, treatment end (4-9 weeks), and 8-week follow-up	Quality and patterns of sleep will be measured with the Pittsburgh Sleep Quality Index, with total scores ranging from 0 to 21; a total score of 5 or greater is indicative of poor sleep. Sleep quality of both participant and study partner will be assessed.
Caregiver Burden Inventory Short-Form	at baseline, treatment end (4-9 weeks), and 8-week follow-up	Caregiver burden will be assessed by the Caregiver Burden Inventory Short-Form, a 12-question inventory that measures the degree of stress experienced by caregivers concerning the effect of the participant's disability on care partners' lives. Total score range from 0-48, with higher score indicating higher burden

Trial Locations

Locations (1)

Li Lab, Icahn School of Medicine at Mount Sinai; 🇺🇸 New York, New York, United States